CING
Price
$0.78
Change
-$0.01 (-1.27%)
Updated
May 17, 6:59 PM EST
CYBN
Price
$0.35
Change
-$0.00 (-0.00%)
Updated
May 17, 6:59 PM EST
39 days until earnings call
Ad is loading...

CING vs CYBN

Header iconCING vs CYBN Comparison
Open Charts CING vs CYBNBanner chart's image
Cingulate
Price$0.78
Change-$0.01 (-1.27%)
Volume$10.77K
CapitalizationN/A
Cybin
Price$0.35
Change-$0.00 (-0.00%)
Volume$1.15M
CapitalizationN/A
View a ticker or compare two or three
CING vs CYBN Comparison Chart

Loading...

CINGDaily Signal changed days agoGain/Loss if shorted
 
Show more...
CYBNDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
CING vs. CYBN commentary
May 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CING is a Sell and CYBN is a StrongSell.

COMPARISON
Comparison
May 18, 2024
Stock price -- (CING: $0.80 vs. CYBN: $0.35)
Brand notoriety: CING and CYBN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CING: 14% vs. CYBN: 40%
Market capitalization -- CING: $4.85M vs. CYBN: $262.59M
CING [@Biotechnology] is valued at $4.85M. CYBN’s [@Biotechnology] market capitalization is $262.59M. The market cap for tickers in the [@Biotechnology] industry ranges from $593.52B to $0. The average market capitalization across the [@Biotechnology] industry is $2.75B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CING’s FA Score shows that 1 FA rating(s) are green whileCYBN’s FA Score has 0 green FA rating(s).

  • CING’s FA Score: 1 green, 4 red.
  • CYBN’s FA Score: 0 green, 5 red.
According to our system of comparison, CYBN is a better buy in the long-term than CING.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CING’s TA Score shows that 2 TA indicator(s) are bullish while CYBN’s TA Score has 4 bullish TA indicator(s).

  • CING’s TA Score: 2 bullish, 7 bearish.
  • CYBN’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, CYBN is a better buy in the short-term than CING.

Price Growth

CING (@Biotechnology) experienced а +5.37% price change this week, while CYBN (@Biotechnology) price change was -3.45% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.41%. For the same industry, the average monthly price growth was +2.86%, and the average quarterly price growth was +60.72%.

Reported Earning Dates

CING is expected to report earnings on Mar 08, 2024.

CYBN is expected to report earnings on Aug 12, 2024.

Industries' Descriptions

@Biotechnology (+1.41% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for CING with price predictions.
OPEN
A.I.dvisor published
a Summary for CYBN with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
CYBN($263M) has a higher market cap than CING($4.85M). CYBN YTD gains are higher at: -14.634 vs. CING (-89.518).
CINGCYBNCING / CYBN
Capitalization4.85M263M2%
EBITDAN/AN/A-
Gain YTD-89.518-14.634612%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
TECHNICAL ANALYSIS
Technical Analysis
CINGCYBN
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
70%
Bearish Trend 1 day ago
86%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
80%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
79%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 4 days ago
87%
Bullish Trend 2 days ago
82%
Declines
ODDS (%)
Bearish Trend 8 days ago
90%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 5 days ago
85%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
CINGDaily Signal changed days agoGain/Loss if shorted
 
Show more...
CYBNDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LOMGX27.520.06
+0.22%
Lord Abbett Growth Opportunities F3
RYVVX81.150.10
+0.12%
Rydex S&P 500 Pure Value C
PRMSX35.440.02
+0.06%
T. Rowe Price Emerging Markets Stock
PSOAX25.510.01
+0.04%
JPMorgan Small Cap Value A
DTMGX40.49N/A
N/A
BNY Mellon Tax Managed Growth A

CING and

Correlation & Price change

A.I.dvisor tells us that CING and ELVN have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CING and ELVN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CING
1D Price
Change %
CING100%
+1.51%
ELVN - CING
29%
Poorly correlated
-3.23%
SLNO - CING
28%
Poorly correlated
+1.10%
CALA - CING
27%
Poorly correlated
N/A
ADPT - CING
26%
Poorly correlated
-2.96%
CYTK - CING
26%
Poorly correlated
-0.65%
More

CYBN and

Correlation & Price change

A.I.dvisor tells us that CYBN and SNPX have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CYBN and SNPX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYBN
1D Price
Change %
CYBN100%
-0.57%
SNPX - CYBN
30%
Poorly correlated
-3.26%
HEPA - CYBN
29%
Poorly correlated
+4.84%
ATAI - CYBN
27%
Poorly correlated
-8.06%
CING - CYBN
25%
Poorly correlated
+1.51%
ARWR - CYBN
24%
Poorly correlated
-0.92%
More